News headlines about NuCana (NASDAQ:NCNA) have trended somewhat positive recently, Accern reports. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NuCana earned a news impact score of 0.04 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 45.5657531776749 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

NCNA stock opened at $23.00 on Friday. The company has a market cap of $749.15 and a P/E ratio of -21.70. NuCana has a 1-year low of $9.32 and a 1-year high of $30.41.

Separately, Zacks Investment Research raised NuCana from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Wednesday, January 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. NuCana presently has an average rating of “Buy” and an average price target of $21.00.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.

Insider Buying and Selling by Quarter for NuCana (NASDAQ:NCNA)

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with's FREE daily email newsletter.